Outcomes of extracranial stereotactic body radiation therapy for induced oligometastatic non-small cell lung cancer on novel systemic therapy

CONCLUSIONS: This study indicates that SBRT for OpersisD or OprogD in Stage IV NSCLC patients on osimertinib or ICIs is safe, very well tolerated, and may prolong the time before needing a shift in systemic therapy. Further prospective research is needed to validate and expand upon these findings.PMID:38601442 | PMC:PMC11002507 | DOI:10.21037/tlcr-23-802

Source: Cell Research - April 11, 2024 Category: Cytology Authors: Eyal Tsur Philip Blumenfeld Yakir Rottenberg Hovav Nechushtan Johnathan Arnon Ori Wald Uzi Izhar Raphael Pfeffer Aron Krakow Marc Wygoda Aron Popovtzer Tal Falick Michaeli Source Type: research